title: The Effects of Physiological and Methodological Determinants on 18F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model.
abstract: In this study, the influence of physiological determinants on 18F-fluoro-d-glucose ((18)F-FDG) brain uptake was evaluated in a mouse model of Alzheimer disease.
  
  
  
  TASTPM (Tg) and age-matched C57BL/6 J (WT) mice were fasted for 10 hours, while another group was fasted for 20 hours to evaluate the effect of fasting duration. The effect of repeatedly scanning was evaluated by scanning Tg and WT mice at days 1, 4, and 7. Brain (18)F-FDG uptake was evaluated in the thalamus being the most indicative region. Finally, the cerebellum was tested as a reference region for the relative standard uptake value (rSUV).
  
  
  
  When correcting the brain uptake for glucose, the effect of different fasting durations was attenuated and the anticipated hypometabolism in Tg mice was demonstrated. Also, with repeated scanning, the brain uptake values within a group and the hypometabolism of the Tg mice only remained stable over time when glucose correction was applied. Finally, hypometabolism was also observed in the cerebellum, yielding artificially higher rSUV values for Tg mice.
  
  
  
  Corrections for blood glucose levels have to be applied when semiquantifying (18)F-FDG brain uptake in mouse models for AD. Potential reference regions for normalization should be thoroughly investigated to ensure that they are not pathologically affected also by afferent connections.
authors.affiliation: Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
authors.forename: Steven
authors.initials: S
authors.lastname: Deleye
authors.affiliation: Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
authors.forename: Ann-Marie
authors.initials: AM
authors.lastname: Waldron
authors.affiliation: R&D China UK Group, GlaxoSmithKline, Stevenage, United Kingdom.
authors.forename: Jill C
authors.initials: JC
authors.lastname: Richardson
authors.affiliation: Neuroscience Department, Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: Mark
authors.initials: M
authors.lastname: Schmidt
authors.affiliation: Neuroscience Department, Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: Xavier
authors.initials: X
authors.lastname: Langlois
authors.affiliation: Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium Nuclear Medicine Department, University Hospital Antwerp, Antwerp, Belgium.
authors.forename: Sigrid
authors.initials: S
authors.lastname: Stroobants
authors.affiliation: Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium Steven.Staelens@uantwerpen.be.
authors.forename: Steven
authors.initials: S
authors.lastname: Staelens
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002531:Cerebellum / Q000000981:diagnostic imaging; D004195:Disease Models, Animal; D005215:Fasting / Q000502:physiology*; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D059906:Neuroimaging / Q000379:methods; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D013788:Thalamus / Q000000981:diagnostic imaging*
chemical_list: D001786:Blood Glucose; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: 18F-FDG; Alzheimer; SUV; brain PET; mouse